INmune Bio Inc. – Consensus Indicates Potential 30.1% Upside

Broker Ratings

INmune Bio Inc. with ticker code (INMB) have now 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 32 and 15 calculating the mean target price we have 26. With the stocks previous close at 19.99 this would imply there is a potential upside of 30.1%. There is a 50 day moving average of 20.16 and the 200 day MA is 12.13. The market cap for the company is $274m. Visit the company website at:

INmune Bio, a clinical-stage immunotherapy company, focuses on reprogramming the patient’s innate immune system to treat cancer Alzheimer’s disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer’s disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio was founded in 2015 and is headquartered in La Jolla, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index